We live Biotech

Zentynel backs bold Latin American founders as a value chain
investor shaping global biotech with a One Health perspective.

About Zentynel

Zentynel is Latin America’s first specialist biotech venture capital fund

Founded through the convergent vision of Fundación Ciencia & Vida and Venturance Alternative Assets, we combine capital, scientific depth, and operational expertise to help founders turn breakthrough science into scalable businesses.

Laboratory
Scientist Cells

Team members

The Zentynel Fund is led by a group of General Partners with deep expertise in science, entrepreneurship, and investment.

Meet the whole team

Cristián Hernández

With more than two decades of experience in investment and development of biotech companies, Cristián has been CEO, Director of Companies and Research Centers, such as Fundación Ciencia & Vida, Nova Mineralis, Ingalfarma, Phage Labs, among others.

Follow on

Pablo Fernández

With over a decade of experience working in startup development, Pablo is a Director of the Alerce Fund and a board member of Andes Ag, GeneproDX, Done Properly, Polynatural, among other companies.

Follow on

Roberto Loehnert

With more than twenty years of experience in investment and development of alternative assets, Roberto is co-founder of Venturance Investments and member of the board of directors of Clínica Alemana de Santiago, Bbosch, Lippi and Streat Burger, among others.

Follow on

Bernardita Méndez

Bernardita has more than thirty years of experience in regulatory affairs and intellectual property in biomedical companies. She is president and co-founder of Fundación Ciencia y Vida. She also serves on the boards of Fundación Chile, Universidad Andrés Bello, Comunidad Mujer and other organizations.

Follow on

Pablo Valenzuela

After more than four decades of investment and business development in the biotechnology industry, Pablo has developed many cutting-edge medical technologies, such as the hepatitis B vaccine. He co-founded Chiron Corporation in 1982, one of the industry’s early pioneers in genetic engineering. In 2005, his company was acquired by Novartis for $8.9 billion.

Impact

Impact is not an afterthought, it is central to our investment thesis

We adopt a One Health approach, recognizing the interconnectedness 
of human, animal, and environmental health.

Impact

We measure impact at three levels:

Global

Solving pressing challenges with worldwide implications.

Regional

Improving health, sustainability, and economic development in Latin America.

Local

Empowering founders, creating jobs, and strengthening communities.

Portfolio

Our portfolio represents the diversity and depth of biotech innovation emerging from Latin America. These companies are tackling challenges in health, sustainability, and food systems with global solutions.

HeXemBio
Asclepii
Fecundis
Axenya
ViewMind
Xeptiva
Biomakers

HARMONY
ISA
Microterra
Samay
Autem Medical
Multiplai
Descripción de la imagen

BioGratitude

We believe in giving before receiving, helping entrepreneurs succeed, even when they are not a direct fit for our portfolio. This builds trust, strengthens the ecosystem, and creates long-term value for all.